---
title: "智能生物解決方案公司公佈 2025 財年第四季度及全年業績，重點介紹其在美國市場擴展計劃上的進展、收入增長以及運營效率的提升"
description: "公司加快了獲得美國 FDA 510(k) 認證的努力，以推動計劃在法醫用途之外的美國市場擴展"
type: "news"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/253235315.md"
published_at: "2025-08-15T13:32:14.000Z"
---

# 智能生物解決方案公司公佈 2025 財年第四季度及全年業績，重點介紹其在美國市場擴展計劃上的進展、收入增長以及運營效率的提升

> 公司加快了獲得美國 FDA 510(k) 認證的努力，以推動計劃在法醫用途之外的美國市場擴展

Company advanced efforts to secure U.S. FDA 510 ( k ) clearance to advance on path towards planned U.S. market expansion beyond Forensic Use Only settings ...

### Related Stocks

- [INBS.US - Intelligent Bio Solutions](https://longbridge.com/zh-HK/quote/INBS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Intelligent Bio Solutions Regains Nasdaq Compliance After Bid Price Recovery | Intelligent Bio Solutions Inc. has regained compliance with Nasdaq's minimum bid price requirement after its stock maint | [Link](https://longbridge.com/zh-HK/news/271989471.md) |
| Intelligent Bio Solutions Signs Multiple Financing Agreements | Intelligent Bio Solutions has signed multiple financing agreements to complete a $10 million private placement of common | [Link](https://longbridge.com/zh-HK/news/271365754.md) |
| Ibn Al Haytham Hospital FY Income 301,281 Dinars | Ibn Al Haytham Hospital Company PSC (IBNH.AM):IBN AL HAYTHAM HOSPITAL FY NET INCOME AFTER TAX 301,281 DINARSIBN AL HAYTH | [Link](https://longbridge.com/zh-HK/news/275996849.md) |
| Did Analyst Upgrades and Metal Price Tailwinds Just Shift Coeur Mining's (CDE) Investment Narrative? | Recent analyst upgrades for Coeur Mining, alongside rising gold and silver prices, have shifted focus on the company's c | [Link](https://longbridge.com/zh-HK/news/275995095.md) |
| Aberdeen Group plc Has $144.09 Million Position in Arista Networks, Inc. $ANET | Aberdeen Group plc increased its stake in Arista Networks, Inc. by 1.4% in Q3, owning 1,005,027 shares valued at $144.09 | [Link](https://longbridge.com/zh-HK/news/275999141.md) |

---

> **免責聲明**：本文內容僅供參考，不構成任何投資建議。